Description: Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Home Page: www.denalitherapeutics.com
DNLI Technical Analysis
161 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 866 8548
Officers
| Name | Title |
|---|---|
| Dr. Ryan J. Watts Ph.D. | Co-Founder, Pres, CEO & Director |
| Dr. Alexander O. Schuth M.D. | Co-Founder, CFO, COO & Sec. |
| Dr. Marc Tessier-Lavigne Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
| Dr. Carole Ho M.D. | Chief Medical Officer & Head of Devel. |
| Mr. Steve Edward Krognes | Treasurer & Director |
| Mr. Tyler M. Nielsen | Sr. VP of Corp. Fin. |
| Dr. Dana Andersen | Chief Technical and Manufacturing Officer |
| Mr. Joe Lewcock | Chief Scientific Officer |
| Dr. Laura Hansen | VP of Investor Relations |
| Mr. Chris Walsh | Gen. Counsel |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7475 |
| Price-to-Sales TTM: | 35.6178 |
| IPO Date: | 2017-12-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 413 |